New approach identifies reproducible volatile organic compounds for lung cancer diagnosis
A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...
FiercePharma1d
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
News Medical2d
Study uncovers how MAGE-4 and Pten loss promote aggressive tumor growth
A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.
Health Canada approves MSD’s Keytruda for NSCLC stages
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Targeted Oncology4d
AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation
The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...
Cure Today4d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
PharmiWeb4d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...